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Introduction Note 
Flanders Marine Institute (VLIZ) participates in public consultations of the 
European Commission on specific marine policy issues. Such consultations help 
the European Commission to collect and use the views of a broad range of 
stakeholders in shaping its discussions, in generating new policies, and in 
improving existing ones. VLIZ provides summaries of its responses to these 
consultations in the form of policy-informing briefs (PIBs). 
The content of VLIZ policy-informing briefs combines expert scientific opinion 
with objective data and information. For this purpose, VLIZ draws on the 
expertise of coastal and marine scientists within its national and international 
network of marine research. 
Policy-informing briefs reflect the impartial and objective position of VLIZ and are 
motivated by the basic principles of sustainable development and an ecosystem 
based approach, as endorsed by the European Integrated Maritime Policy and the 
principles of integrated coastal zone management.  
More information about the core business, principles and terms of reference of 
the VLIZ: http://www.vliz.be/en/mission. 
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GENERAL  CONTEXT  ON  MARINE  BIOTECHNOLOGY 
 
Marine biotechnology has the potential to help in addressing some of today's 
greatest challenges, including those relating to health, food supply, 
environmental sustainability, energy security and others. At the same time the 
introduction of new high value added products and processes into the market can 
stimulate economic growth, leading to the creation of new high-quality jobs. This 
is why this nascent industry has been highlighted as one of the five blue growth 
focus areas in the Communication from the European Commission on "Blue 
Growth: opportunities for marine and maritime sustainable growth", adopted on 
13 September 2012.  
Marine ecosystems are much more biologically diverse than terrestrial 
ecosystems, yet they have been so far explored and exploited to a much lesser 
extent. As the research technologies advance, however, we are increasingly able 
to access valuable marine resources. The incredible diversity of marine life can 
translate into a wide range of useful applications. Marine Biotechnology can be 
defined as the use of marine bioresources as the target or source of biotechnical 
applications. Enhancing aquaculture productivity through containment and 
rearing technology is an example of the former, more established applications of 
biotechnology. Modern applications include for example the derivation of drugs 
from marine sponges, fuel from microalgae and environmental monitoring 
technologies. 
Cutting-edge innovative applications of marine biotechnology currently only takes 
the form of a niche market of high value added products and processes. 
However, some suggest that there is a strong potential for it to grow and develop 
further to become an important contribution to smart, inclusive and sustainable 
growth in Europe. In this context, the European Commission may develop an 
impact assessment study, which would explore the potential of the marine 
biotechnology sector into detail, propose possible options to facilitate the 
development of the sector and analyse their corresponding social, environmental 
and economic impacts and inform further policy steps.  
To produce this document, Flanders Marine Institute (VLIZ) worked closely 
together with the Federal Public Service Health, Food chain safety and 
Environment (FPS Health) and the Belgian Science Policy Office (Belspo), 
concerning the achievements and potential growth for the marine biotechnology 
sector. FPS Health and Belspo responded separately to the consultation providing 
input from a governmental point of view whereas VLIZ provided in its response 
input from a scientific point of view. Where relevant, information of the other 
party was included in the response. All parties agreed on the response to the 
consultation that is summarized below.  
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POTENTIAL  AND  FUTURE  TRENDS 
 
Quantification and potential growth 
VLIZ, FPS Health and Belspo are of the opinion that marine biotechnology has a 
strong potential to grow in the future. In particular, marine biotechnology 
applications in the areas of health and well-being (e.g. pharmaceuticals, 
nutraceuticals and cosmetics), food (e.g. fisheries and aquaculture) and 
environment (e.g. remediation, environmental monitoring) could have high 
growth potential in financial terms, whereas the potential growth for energy 
applications is believed to be rather low. Yet, there is little information available 
allowing the quantification of this potential growth. 
It should be noted that the research field of blue marine biotechnology is still in 
full development and various barriers still exist to develop, test and 
commercialize scientific findings. Therefore, at this moment, it is not possible to 
indicate the growth potential of the different application areas. From a 
government policy point of view, it is important to stimulate research in a wide 
range of “marine biotech fields”. Given the vastness of the marine environment 
and the increased use of the marine area, development in “remote sensing” in 
the broad sense (environmental monitoring, safety, surveillance, …) may have a 
specific potential for growth. On the other hand, given the vast number of 
species, yet undescribed from the deep sea, there is a potential for the use of 
these “genetic resources’ for the development of marine-derived molecules 
exploitable by industry including enzymes, biopolymers and biomaterials. For 
example, microalgae form an important alternative feed in aquaculture and can 
also be produced as an alternative source of omega-3 fatty acids (as opposed to 
fish-oil derived omega-3 FA), thus reducing the pressure on the already over-
exploited fish stock. 
For the general biotechnology sector of Belgium, following information is available 
for 2011: there are 350 biotechnology firms (i.e. using biotechnology to produce 
goods or services and/or to perform biotechnology R&D) of which 127 (i.e. 36%) 
firms devote at least 75% of their production of goods and services, or R&D to 
biotechnology (OECD, 2013b). Without being able to give precise numbers, the 
share of marine biotechnology within this general biotechnology sector in Belgium 
is currently limited to very limited. Projects and networks in which Belgian 
institutes are involved, are amongst others: PharmaSea, Microalgae, Special 
chemicals, MicroB3, Vlaams Algenplatform and Marien Biotechnologie platform 
Vlaanderen. A list of other international projects involving marine biotechnology 
activities can be found in the following database: 
http://www.marinebiotech.eu/projects?module=project&show=search. The 
framework of this project database has been developed under the FP7 
Coordination and Support Action on Marine Biotechnology, CSA MARINEBIOTECH 
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(October 2011-March 2013) and will be further expanded during the ERA-
MarineBiotech (December 2013-November 2017). 
For general considerations on the growth of marine biotechnology on EU level, 
the EMB Position Paper 15 (2010) states that marine biotechnology can not only 
create jobs and wealth, but that it can also contribute to the development of 
greener, smarter economies, central components of the new Europe 2020 
Strategy. In OECD (2013b) the economic contribution of the oceans is calculated 
for the United Kingdom, Canada and the United States. However, a global 
estimation is not yet possible. 
Considering the global market for marine biotechnology, the EMB Position Paper 
15 (2010) states that: “ the global market for Marine Biotechnology products and 
processes is currently estimated at € 2.8 billion (in 2010) with a cumulative 
annual growth rate of 4-5%. Less conservative estimates predict an annual 
growth in the sector of up to 10-12% in the coming years, revealing the huge 
potential and high expectations for further development of the Marine 
Biotechnology sector at a global scale.” 
The value of a few markets is estimated in the publication from OECD (2013b): 
 Pharmaceutical products: 
 sponge, Cryptotethya crypta: compounds with anti-viral 
(Ara-A) and anti-leukemic (Ara-C) properties which have 
an annual market of USD 50-100 million; 
 soft coral, Pseudoterigorgia elisabethae: bioproducts used 
in skin care and cosmetics lines which are currently worth 
USD 3-4 million a year.  
 
 Biotechnology: 
 Taq polymerase and other synthetic polymerases with 
similar properties is now used in biotechnology 
laboratories worldwide and represents a considerable 
market: sales of Taq DNA polymerase in Europe alone 
were USD 26 million in 1991 (Roberts, 1992) and had an 
initial estimated annual market of USD 50-100 million. 
The market for DNA polymerases is now believed to be in 
the order of USD 500 million a year.  
 
 Fish and shellfish: the contribution of marine biotechnology to 
production and market value is not known.  
 
 Biomass-related markets: 
 Seaweed-derived polysaccharides (including those derived 
from agar, alginates and carrageenan) have mature and 
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relatively stable markets: 86 000 tonnes and USD 1 018 
billion in 2010 (Bixler and Porse, 2010). 
 Globally the markets for chitin and chitosan (both largely 
marine-derived) are worth USD 481 million and are dwarfed 
by the market for chitin and chitosan derivatives (e.g. 
glucosamine) which are forecast to reach USD 63 billion and 
USD 21.4 billion, respectively, by 2015. 
 The market for functional foods and natural products, 
including dietary supplements, natural and organic foods and 
beverages, functional foods and beverages, and natural and 
organic personal care and household products, was estimated 
at USD 270 billion in 2008 and is forecast to grow at around 
6% through 2015. Again, with a few notable exceptions, it is 
difficult to separate out the fraction derived from marine 
bioresources.  
 The global market for marine and algae oil omega-3 
ingredients, estimated at USD 244 million in 2009, is forecast 
to reach USD 476-664 million by 2015 (based on estimated 
annual growth rates of 10.9% to 17.3%).  
 Markets & Markets has also forecasted that the aquaculture 
feed market will grow with 11.7% from 2013 to 2018, 
becoming a 1.2 billion$ market. Algae are a more sustainable 
alternative to fish meal for this application and the growth of 
this market only confirms the great potential of algae culture.  
In OECD (2013b) it is stated that some believe that the potential of marine 
biotechnology is equal to that of land-based biotechnology, but that the field is 
too young to be measured by economic output indicators and should be 
measured using R&D and innovation. 
 
Benefits 
Benefits of the marine biotechnology development from a private, national and 
regional perspective are described in the key highlights of the CSA MarineBiotech 
Public Report (2013): 
•  Sharing knowledge between researchers and private companies.  
•  The early involvement of firms in research projects creates the potential to 
develop a market focus or a utility aspect. 
 • Achieving a diversity of participation and a balance of regional representation.  
•  Capturing new disciplinary expertise and competencies, opening access to 
infrastructures and drawing from specific regional experiences in marine 
biotechnology. 
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•  Efforts that give greater focus to areas where Europe has already established 
unique competencies, or by exploiting natural resources that offer exceptional 
potential and opportunities for member states are likely to offer long-term 
success. The impact of this approach, particularly where opportunities are 
relevant to economic and societal challenges is considered to be of greater value, 
than a purely scientific oriented one. Successful implementation of the strategy 
will require a joint effort with active support and involvement from all relevant 
stakeholders. Europe needs to mobilise the necessary support in terms of 
funding, human resources and research infrastructures, and to secure the 
engagement of all of the relevant actors. These actors include the science 
community, the private sector (e.g. individual companies, associations and 
technology platforms) policy makers and advisors at national and European level, 
national strategy and programme developers and managers, and ultimately the 
public at large. As each actor has an important responsibility to bring forward key 
elements of the strategy, mobilising, in a coordinated way, this diverse range of 
actors will be critical.  
 
Economic impact 
According to VLIZ, FPS Health and Belspo the development of marine 
biotechnology has a positive impact on the bioeconomy by creating jobs 
throughout the value chain from academic positions to positions in industry. It is 
also expected to affect many value-added sectors: pharmaceuticals, food, 
industrial processing, nutraceuticals, etc. (OECD, 2013b). The application of new 
genomic knowledge and technologies in aquaculture can create new job 
opportunities, both in the coastal and non-coastal populations. It could also 
create a shift from more traditional jobs. 
In addition, VLIZ, FPS Health and Belspo believe that there is also a significant 
potential for exports from the EU to third countries. Marine biotechnology can 
help to address global challenges related to food, fuel security, population health 
and sustainable industrial and environmental processes. However, developing 
countries face challenges for accessing new technologies and financial capital, for 
example in the field of molecular aquaculture, which is especially important in the 
context of the growing consumption of animal protein, expected to double in the 
first half of this century (OECD, 2013b). The different rate at which these 
technologies are developing in different countries could potentially limit the 
productivity gains and sustainability of the progress in these domains. Therefore 
it is advised to anticipate by allowing/facilitating third countries to participate in 
the “EU marine biotech research arena” and by exporting advanced technologies 
and products to third countries.  
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BARRIERS  TO  GROWTH 
 
Marketing 
VLIZ, FPS Health and Belspo consider the greatest barriers for bringing marine 
biotechnology applications into the market to be the lack of a legal framework, 
the lack of collaboration (including between academic and industrial partners / 
difficulty in finding partners for collaboration) and access to finance.  
The lack of a framework beyond the national jurisdiction raises questions about 
ownership, access to the bioresources and the sharing of the benefits to be 
obtained. If no clear governance framework is in operation, progresses in marine 
biotechnology are likely to be delayed or sustainable use of bioresources is at 
risk. 
Other potential challenges for the marketing of biotechnology applications are 
believed to be the lack of knowledge (by traditional biotechnology players) about 
the potential of marine genetic resources for biotechnology applications and the 
lack of established marine biotechnology value chains or entry points in the 
already existing ones. The complexity of marine ecosystems and the comparative 
lack of in-depth knowledge of marine bioresources and their interaction with 
ecosystems implies that precautions should be taken for the sustainable use of 
those resources and their ecosystem services. Great attention to scientific 
research should be made to protect the shared resources of the interconnected 
world’s oceans. Bottlenecks in the marine pharmaceutical pipeline include 
insufficient funding for basic marine pharmacology and technical challenges for 
the characterisation of unknown taxa and gene functions (OECD, 2013b). The 
main challenges facing pharmaceutical discovery from marine bioresources are 
linked to: legal aspects (secure access to marine resources, property rights and 
intellectual property); quality of marine resources (identification and variability); 
technology (screening of active compounds and dereplication, preventing 
repeated rediscovery); and structural costs of drug discovery from natural 
products and especially marine products (EMB Position Paper 15, 2010). 
VLIZ, FPS Health and Belspo also suggest that an increase in visibility of the 
sector could also enhance the marketing of marine biotechnology applications. 
Finally, the involved risks, the availability of support mechanisms (e.g. innovation 
incubators, etc.) and the available capacity (e.g. suitably trained personnel, etc.) 
are believed to pose less of a challenge for the marketing of marine 
biotechnology applications, at this time. 
Research innovations 
According to VLIZ, FPS Health and Belspo the greatest challenges encountered in 
research are the lack of collaboration, a lack of funding (regional, national and 
EU-level) and complexities of obtaining funds. Early collaboration between 
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industry and academia (industry-academic partnerships) should be encouraged 
early in the process to support co-development of knowledge and innovations in 
the market place. This is to ensure that the products of marine biotechnology 
research are suitable for scaling up to industrial production. Collaboration is 
needed on an international level (ERA-MarineBiotech), including third countries. 
Also, limited access to research infrastructure (e.g. research vessels, 
laboratories) could pose a barrier to research. 
Finally, VLIZ, FPS Health and Belspo are of the opinion that available capacity 
(e.g. suitably trained personnel, etc.), legal frameworks (e.g. unclear intellectual 
property) and access to marine genetic resources or sufficient amounts of marine 
organisms for downstream biotechnology research and development (e.g. 
sampling, repositories, biobanks, rights, patenting rules, etc.) pose less of a 
challenge to innovative research, at this time. 
 
SUSTAINABILITY  AND  ETHICS 
 
Environmental impact 
VLIZ, FPS Health, Belspo consider bioprospecting in a delicate ecosystem to have 
potential negative environmental impacts. In situ activities are likely to introduce 
(unfamiliar, heightened) light, noise, change of water temperature, pollution, 
debris, biological contamination and overexploitation. Extraction of samples can 
also have an influence on life cycle, characteristics, distribution and population. 
This concern may increase when there is a cumulative impact suffered by the 
source organism, for example: krill is not only being harvested, but also suffers 
from reduced sea ice, leading to cumulative pressure on the species. In general, 
bioprospection is limited to sampling, which requires the extraction of relatively 
small amounts of material. Research indicates that such sampling may not have a 
large impact on the fragile organism or delicate ecosystem the sample is collected 
from. Bioprospection and biodiversity conservation need to go hand in hand, as 
the former benefits from the latter. However, repeated collection, when a species 
has shown biotechnological potential and value, may require greater quantities 
and may raise the likelihood of environmental impact. On top of this, at this 
stage, very little is known about marine ecosystems and species – especially deep 
sea ecosystems and extremophiles – and it is this uncertainty which warrants the 
application of the precautionary approach (UNEP, 2013). 
VLIZ, FPS Health, Belspo also acknowledge the positive impacts of marine 
biotechnology on the environment. Microalgae, for example, form an important 
alternative feed in aquaculture and can also be produced as an alternative source 
of omega-3 fatty acids (as opposed to fish-oil derived omega-3 FA), thus 
reducing the pressure on the already over-exploited fish stock. Another example 
put forward is algal biofuel production that can reduce environmental pressure as 
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the source does not compete with food production like other biofuels. In addition, 
the cultivation of microalgae has a smaller physical footprint and carbon- or 
nitrogen-rich waste gas streams provide an opportunity to biofix greenhouse 
gases.  
Marine biotechnology can help to ensure the sustainable use of biomass through 
the development of new culture, production and processing techniques and 
practices (OECD, 2013b). Moreover, marine biotechnology can also provide a 
means of monitoring and even remediating the marine environment through 
biosensor and bioremediation applications. Since 2001, rapid biological and 
biotechnological progress has resulted in a more efficient and environmentally 
responsible aquaculture and a greater diversity of marine food products. (EMB 
Position Paper 15, 2010)  
 
Social impact 
According to VLIZ, FPS Health and Belspo, the impact of bioprospecting on 
marine ecosystems is not to that extent that it would influence other sectors, 
such as fisheries or that it would influence coastal populations. There is, on the 
other hand, already interaction between other users of the marine environment 
and researchers, who often use existing cruises as means of transportation for 
their research. Public-private cooperation is in that sense relevant. As we live in a 
more globalized world now and taking into account that marine biotechnology will 
encompass the entire marine part of the world, the impact will be of benefit to 
coastal populations but most important to the users of the marine space. The 
OECD (2013b) recognizes the bioeconomy as a political priority because of its 
tremendous potential for economic growth and social benefits. It considers that 
the bioeconomy will allow US citizens to live longer, healthier lives, reduce 
national dependence on oil, address key environmental challenges, transform 
manufacturing processes, and increase the productivity and scope of the 
agricultural sector while creating new jobs and industries. Marine biotechnology 
can make an important contribution to the bioeconomy through the development 
of innovative products and processes, the creation of jobs and the building or 
greening of a number of industries and sectors.  
The development of marine biotechnology will have an impact on the population 
as a result of the products that are produced. Marine biotechnology has led to the 
development and production of a number of pharmaceuticals, nutraceuticals, 
nutrition supplements, cleaning products, other consumer products. It is also 
important to consider the non-market value of the oceans, e.g. the environmental 
(ecosystem services) and recreational value that can be derived from the ocean, 
and to recognize how these are affected, positively and negatively, by marine 
biotechnology applications. This affects the entire population on earth.  
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Ethical issues 
VLIZ, FPS Health and Belspo are of the opinion that there are no adequate 
arrangements in place to ensure an equitable distribution of the benefits of 
marine biotechnology.  
They refer to the OECD (2013b) which states that marine biodiscovery is already 
taking place in the open ocean and the international seabed, marine areas 
beyond the limits of national jurisdiction, and is expected to increase. The CBD 
(Convention on Biological Diversity) and Nagoya Protocol only apply to the 
continental shelves and exclusive economic zones (EEZs) of their contracting 
parties, and therefore do not address marine genetic resources obtained from 
these areas. At present, such resources are accessible to anyone for any purpose. 
There is no formal obligation to share benefits with the international community, 
although the United Nations Convention on the Law of the Sea (UNCLOS) does 
have provisions on international co-operation and the exchange of results with 
respect to marine scientific research in these areas. While it is important to reach 
a shared understanding of “countries providing genetic resources” and “local” 
providers and a better understanding of the role and value of traditional 
knowledge, particularly to ensure legal certainty in the discovery and 
development of marine bioresources, the equitable development of marine 
genetic resources in areas beyond national jurisdictions may provide even greater 
challenges. New governance frameworks should be put in place to deal with these 
issues. UNCLOS was adopted at a time when the international community was 
unaware of marine genetic resources and their potential and although it has 
provisions for metallic/gaseous/… substances, it is silent on living genetic 
resources. UNCLOS’s general rules on activities at sea (such as a duty to preserve 
the marine environment) are obviously applicable to bioprospecting in areas 
beyond national jurisdiction, but there are no provisions on benefit sharing. This 
is why Belgium and the EU have been arguing for the start of negotiations of an 
additional protocol to the UNCLOS (an “Implementing Agreement for biodiversity 
in areas beyond national jurisdiction”) within the relevant UN working group and 
in other high level fora (such as Rio+20). This Implementing Agreement would, 
amongst others, create a system where biodiversity is protected and preserved 
and where access and benefit sharing is regulated. This system needs to be 
balanced in such a way that genuine needs of the developing world are met (for 
example: capacity-building for experts and scientists from developing countries, 
transfer of technology, database of activities, fair system of patenting,…), but 
investments from other States, as well as private entities are not hazarded.  
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INNOVATION  PATHWAYS,  DATA-SHARING  AND  INTERNATIONAL  
COOPERATION 
 
'Open innovation' 
VLIZ, FPS Health and Belspo believe that ‘open innovation’, i.e. innovating with 
partners by sharing risk and sharing reward, is possible. Moreover, effective 
partnerships will play a large role in developing marine biotechnology and in 
translating new scientific and technological knowledge into social and economic 
benefits. Successful innovation will require partnership with stakeholders 
throughout the innovation cycle: suppliers, consumers, competitors, private R&D 
firms, universities and higher education institutions, and government and public 
research institutes. It will be important to understand the types of partnerships 
that facilitate innovation and the mechanisms that are effective for initiating and 
supporting them (OECD, 2013b). Incentives or other support may be required to 
encourage academics and other actors in basic research to participate in the full 
innovation cycle up to commercialisation. To achieve an appropriate balance 
between basic and applied research in advancing marine biotechnology will also 
require business models for developing and producing marine biotechnology 
products and services that ensure the right incentives and support (OECD, 
2013b). It is advised to anticipate by allowing/facilitating third countries to 
participate in the “EU marine biotech research arena” and by exporting advanced 
technologies and products to third countries.  
 
Models and initiatives for knowledge sharing 
With regards to potential collaborative models and types of initiatives for 
knowledge sharing, VLIZ, FPS Health and Belspo refer to OECD (2013b): “some 
forms of collaboration are listed which have proven successful for some sectors in 
facilitating knowledge sharing: collaborative research, university-industry 
research centres, contract research and academic consulting. Other examples 
are: platforms, public-private partnership and collaboration with SME’s (Small 
and Medium Enterprises). A good example is the Marine Biotech Platform of 
Flanders (in Dutch: Marien Biotechnologie Platform Vlaanderen, website: 
http://www.mariene-biotechnologie.be/). This Platform forms a network of 
industrial and scientific partners with the aim of increasing the visibility of marine 
biotechnology so that it can contribute to the general recognition of the research 
and may lead to improved cooperation and the promotion of interdisciplinarity. 
VLIZ performs a facilitating role. In addition, VLIZ collects relevant information 
(contact database, project database, job vacancies, events,…) and publishes 
these on the website and through a LinkedIn group. 
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The formation of dedicated clusters  
VLIZ, FPS Health and Belspo see the formation of dedicated clusters, i.e.  
geographic concentration of interconnected businesses, suppliers, and associated 
institutions in a particular field, as beneficial for the development of marine 
biotechnology. 
They refer to the OECD Innovation Strategy that recognises the impact that fully 
functioning knowledge networks can have on the efficiency and effectiveness of 
the innovation process, both stimulating innovation and improving its efficiency 
by reducing transaction costs. As marine biotechnology becomes a focus of 
investment and innovation strategies, it will be important to ensure that 
mechanisms are in place to generate, share and give value to knowledge in order 
to enable innovation. Given the global nature of marine bioresources, it will also 
be useful to consider international, transboundary approaches that can help to 
drive innovation in R&D infrastructure (OECD, 2013b). Marine biotechnology 
funding programmes and initiatives are already established of which some 
examples are: EU Joint Programming initiatives (JPI Oceans, …); EU ERA-NET 
(ERA-MarineBiotech, …); Regional partnerships (CIESM, KAUST,…); European 
infrastructures for example the European marine biological centre (EMBRC): a 
research infrastructure for exploring the secrets of marine organisms, open to all 
European researchers. This consortium will deliver services to the marine science 
community, local SMEs and industrial companies by facilitating access to marine 
organisms, their environment and the expertise associated with their study. 
Marine biotechnology funding programmes and initiatives should be promoted in 
the future to increase the value of international partnerships and investment for 
fostering knowledge development. This is also highlighted in the EMB Position 
Paper 15 (2010), which recommends to: 
 stimulate the development of research strategies and programmes for 
Marine Biotechnology research and align these at the national, regional 
and pan-European level.  
 create a European Marine Biotechnology Institute or Centre, at least 
virtual, charged with developing Europe’s Marine Biotechnology research 
capabilities through a range of collaborative actions including establishing 
and operating the European Marine Biotechnology Portal.  
 develop a coherent European Marine Biotechnology RTD policy to 
strengthen the integration at EU level of Marine Biotechnology research 
and corresponding infrastructures, among others through a future 
Framework Programme support action or a dedicated ERA-NET.  
 strengthen common European platforms in the field of omics research 
which include corresponding bioinformatics and e-infrastructures and the 
development of centres for systems biology and synthetic genomics, 
recognising that Marine Biotechnology draws from a wide range of multi-
disciplinary research outputs and tools.  
    
15 | P a g e  
PIB_2014_001  8 May 2014  
 develop high level European Marine Biotechnology research programmes 
taking an industry-academia collaborative and multidisciplinary scientific 
approach in the thematic areas of Food, Energy, Health, Environment and 
Industrial Products and Processes. 
 
Infrastructure sharing 
VLIZ, FPS Health and Belspo suggest some opportunities for infrastructure 
sharing and how these could be developed:  
 omics science (genomics, transcriptomics, proteomics and metabolomics) and 
related technologies have rapidly made great improvements over the last 
decade. Marine organisms can now be examined more quickly and in greater 
detail than ever before, by for instance the use of metagenomic analysis. Also 
the cost is dropping rapidly by the advances in new technologies. OECD 
(2013b) reports a new infrastructure bottleneck that threatens to limit the 
rate at which its benefits can be realised. Moreover, exploration and sampling 
are still difficult in areas of environmental extremes which offer great 
potential for discovering organisms with novel functionalities. International 
cooperation is needed to deal with the technically difficult, expensive and very 
risky cruises. Upgraded infrastructure is needed, with new model, culture 
systems and bioinformatics-based tools to visualise and analyse genomics and 
other types of data. Platforms such as databases and biobanks provide an 
excellent focus for collaboration and the open sharing of data and data 
products. 
 
 Databases are an important tool assembling and sharing different types of 
information. Especially for the study of marine bioresources and biodiversity, 
databases are an integral part allowing an inventory of the different aspects 
within marine biotechnology. Support should be given to the development of 
databases, as established in the ERA-MarineBiotech 
(http://www.marinebiotech.eu/component/imis/?module=institute) and the 
Marine Biotechnology platform Flanders (http://www.mariene-
biotechnologie.be/mariene-biotechnologie-in-vlaanderen). 
 
 The challenge to keep databases up to date implies that access to networks of 
stations, seagoing platforms and observatories is required and this could be 
obtained by the execution of international cooperation projects. Great effort 
should also be made into making these databases publicly accessible, 
ensuring high quality and providing international awareness and cooperation 
and synergies.  
 
 Additional value could be found in databases which are developed by 
cooperation between researchers in research institutes, universities and 
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industry. Meanwhile, sharing of shiptime on research vessels (like the 
EUROFLEETS project), exchange of specific equipment, provide/exchange of 
access to research stations or labs with large infrastructure (like Interact 
project) need to be continued. On an academic level, the Ghent University 
created an interdisciplinary consortium called Marine@UGent (the UGent 
Marine Sciences Center of Excellence), to promote and facilitate the 
collaboration between 30 research groups from 6 faculties and with Flanders 
Marine Institute. Marine@UGent members also perform research in the 
marine biotechnology sector. Marine biotech can also take profit of the 
platforms that have already been built for the red, green and white biotech.  
 
Data ownership and intellectual property issues 
Industry has often access to databases developed with public funding, however 
the converse is rarely executed. VLIZ, FPS Health and Belspo believe that 
consideration should be given to incentives for industry and scientists to work 
together in this area. If there is no competitive disadvantage of sharing private 
data, this should be done directly after monitoring. The assigning authority must 
oblige the contractor to collect data during the contracting phase and give a 
compensation for this effort. In this way the same datasets can be used for 
different purposes and overlap of monitoring surveys can be avoided. Data 
collected with public money should be publically available. This data sharing gives 
everybody the possibility to do their own data assessments. Databases should be 
designed to summarize the information regarding gathered data, to allow efficient 
use of scientific data and avoid research duplication.  
 
International cooperation with third (non-EU) countries 
VLIZ, FPS Health and Belspo believe there is a scope for international cooperation 
with third (non-EU) countries. International cooperation with third countries is 
needed, especially with developing coastal countries that lack the scientific and 
technological capacity to explore and develop resources. Otherwise further 
investment by capacity-rich countries will create further inequities, which can be 
illustrated with the current marine gene patents. The OECD (2013b) summarizes 
a search of the patent division of GenBank from 1999-2009 which identified 677 
international claims of marine gene patents. These patents originated from only 
31 of the world’s 194 countries. Some 90% of these patents belonged to just ten 
countries which account for only 20% of the world coastline. Cooperation with 
research centra in China can provide win-win situations for the study of their 
“large-scale marine bioremediation” activities in the coastal area of the Shandong 
province. China is also investing in R&D for Blue BioEconomy activities. 
Furthermore, marine biotechnology/biodiscovery activities could be a theme for 
trans-Atlantic cooperation between EU and US/Canada. On the other hand this is 
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also a topic where cooperation with developing countries is possible (capacity 
building, knowledge/technological transfer, ...).  
 
WAY  FORWARD 
 
Public intervention 
VLIZ, FPS Health and Belspo believe there is a scope for the EU to support the 
emerging marine biotechnology sector with additional measures. Specific funding 
programs for university-industry partnerships could be supported to accelerate 
the creation and application of knowledge. Knowledge exchange events could be 
organised to foster constructive dialogues between academic researchers and 
industry. Support should be given to the central European information portal 
which was established in the CSA MarineBiotech project, financed under the FP7 
programme. This one-stop-shop for state-of-the-art reports on novel discoveries 
and success stories, challenges and opportunities will be updated within the ERA-
MarineBiotech and continuation beyond this project should be ensured 
(http://www.marinebiotech.eu/wiki).  
Other recommendations to support the emerging marine biotechnology sector are 
highlighted in the EMB Position Paper 15 (2010), advising to:  
 initiate a series of Marine Biotechnology demonstration projects that 
target the utilisation of marine materials in defined sectors.   
 1d) Develop promotional and education support materials that highlight 
the potential and the successes of European Marine Biotechnology 
research.  
 significantly improve technology transfer pathways, strengthen the basis 
for proactive, mutually beneficial interaction and collaboration between 
academic research and industry and secure access and fair and equitable 
benefit sharing of marine genetic resources.  
 better adapt future FP financial rules and Grant Agreements to ensure 
SMEs are attracted to participate in a way that maximises the reward and 
minimises economic risks.  
 establish completely new mechanisms and policies to circumvent the high 
risk of investments in critical novel drugs developed from marine 
bioresources, in particular for the development of new antibiotics of 
marine origin.  
 harmonise the property rights and procedures for the protection of 
intellectual property for marine derived products at European level but 
with a global relevance. Develop new European protocols to facilitate the 
publication of academic research results whilst protecting, through 
innovative procedures, the intellectual property on new discoveries. 
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 develop a common European position on the simplification and 
harmonisation of regulations on access and fair and equitable benefit 
sharing from the exploitation of marine genetic resources taking into 
account three ‘territories’: inside Europe; outside Europe and international 
waters.  
 conduct a survey of industry stakeholders to guide research towards 
applications and processes to address current industry needs.  
VLIZ, FPS Health and Belspo believe that public engagement at the 
national/regional level will be necessary to stimulate development of marine 
biotechnology and to advance the policy agenda. It will be important to have an 
ongoing, inclusive dialogue on the opportunities offered by marine biotechnology 
and their environmental implications, and for this dialogue to take place at 
regional, national and international levels. The goals of economic productivity and 
wealth creation need to be seen in terms of the cultural and social well-being and 
not only of coastal populations but of the entire world (OECD, 2013b). 
 
Research and innovation 
According to VLIZ, FPS Health and Belspo effective partnerships will play a large 
role in developing marine biotechnology and in translating new scientific and 
technological knowledge into social and economic benefits. Successful innovation 
will require partnership with stakeholders throughout the innovation cycle: 
suppliers, consumers, competitors, private R&D firms, universities and higher 
education institutions, and government and public research institutes. It will be 
important to understand the types of partnerships that facilitate innovation and 
the mechanisms that are effective for initiating and supporting them. Other 
recommendations are highlighted in the EMB Position Paper 15 (2010), advising 
to: 
 improve training and education to support Marine Biotechnology in 
Europe.  
 assure that appropriate biotechnology modules are included in all bio-
science undergraduate educational programmes.  
 initiate actions that will ensure the participation of researchers from non-
marine backgrounds in Marine Biotechnology, thus ensuring that a 
growing pool of exceptional research talent is available to the Marine 
Biotechnology sector. 
 organise regular trainings or summer schools on Marine Biotechnology 
subjects supported, for example, by the EU Framework Programme. 
 create a European School or Course on Marine Biotechnology (virtual and 
distributed) and a European PhD programme on Marine Biotechnology 
both of which need to include business and entrepreneurship training as 
standard. 
    
19 | P a g e  
PIB_2014_001  8 May 2014  
In addition, VLIZ, FPS Health and Belspo recommend open communication and 
collaboration in the framework of international programmes or communication 
events to prevent the duplication of efforts. Focused and effective international 
dialogue will be needed to address hurdles such as development of indicators, 
R&D infrastructure and sustainable development of marine resources. Dialogue at 
national and regional level among end users, regulators, the private sector and 
researchers will also be important for innovation in marine biotechnology and its 
applications.  
With regards to identifying training that is needed to develop necessary skilled 
scientists/labour, VLIZ, FPS Health and Belspo refer to the EMB Position Paper 15 
(2010): “to promote Marine Biotechnological innovation, training of the next 
generation of scientists is critical. They must have more interdisciplinary 
expertise and use tools from various disciplines to address questions related to 
marine organisms and to solve problems posed by the marine environment”. This 
statement is not specific to marine biotechnology; in fact the future of life 
sciences in the 21st century will depend upon the ability of scientists to develop 
interdisciplinary projects embracing skills and concepts from, for example, 
phylogeny, mathematics, chemistry, and the physical, engineering, computational 
and social sciences. The challenge for the development of the Marine 
Biotechnology sector is to ensure that undergraduate and graduate training 
programmes related to marine sciences include adequate training in 
biotechnology. 
For the international coordination of the marine biotechnology sector VLIZ, FPS 
Health and Belspo believe that JPI Oceans could play role as a strategic 
coordination mechanism with other non-EU countries. They also refer to the CSA 
MarineBiotech Deliverable D3.6 (2013): In spite of the significant progress at 
various fronts, numerous challenges remain. One of the main challenges will be 
to keep stock of all the developments currently taking place and ensure 
appropriate levels of alignment, and integration where required, of the interests, 
strategies, programmes and activities at the local, sub-national regional, national, 
macro-regional (sea basin level), pan-European and international level. How to 
position blue biotechnology in the complicated and dynamic landscape of other 
biotech fields (notably industrial (white) biotech, health [red] biotech and 
agricultural research (green) biotech), the numerous relevant research and 
coordination projects (including the ERA-MarineBiotech and other ERA-NETs), 
infrastructures, the Joint Programming Initiative on Healthy Seas and Oceans etc.  
 
Market introduction 
For suggestions on how to facilitate the interaction between science, industry and 
society, VLIZ, FPS Health and Belspo refer to the key highlights of the CSA 
MarineBiotech Public Report (2013): Successful implementation of the strategy 
will require a joint effort with active support and involvement from all relevant 
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stakeholders. Europe needs to mobilise the necessary support in terms of 
funding, human resources and research infrastructures, and to secure the 
engagement of all of the relevant actors. These actors include the science 
community, the private sector (e.g. individual companies, associations and 
technology platforms) policy makers and advisors at national and European level, 
national strategy and programme developers and managers, and ultimately the 
public at large. As each actor has an important responsibility to bring forward key 
elements of the strategy, mobilising, in a coordinated way, this diverse range of 
actors will be critical.  
The rate of conversion of research findings into market applications is lower in 
Europe compared to other parts of the world. To bridge the gap between research 
and innovation VLIZ, FPS Health and Belspo suggest the early collaboration 
between industry and academia. Industry-academic partnerships should be 
encouraged early in the process to support co-development of knowledge and 
innovations in the market place. They also refer to the key highlights of the CSA 
MarineBiotech Public Report (2013): a common problem, to which ERA-NETs offer 
a solution, is enabling research that a single country could not undertake. The 
synergies from such interaction could be of interest to firms in the private sector, 
since access to a broader skill base is possible and there is a scale effect that 
enhances credibility of the project. However, within such projects, some firms 
may prefer to remain anonymous for competitive reasons. Irrespective of their 
duration, it is essential that projects remain clearly focused on specific 
deliverables. Open ended or vague projects offer little to attract the involvement 
of firms. A challenge remains, concerning where or what areas to focus upon. 
Processes which involve firms in setting goals for ERA-NET projects are preferable 
to those which fail to include firms, since they are more likely to include a 
commercial perspective. The early involvement of firms in research projects 
creates the potential to develop a market focus or a utility aspect. 
In order to use economic data and information (parameters/indicators) to (i) 
allow a more objective market/trend analysis to assess the size and development 
of the sector and (ii) to assess the return on (public) investment in the sector, 
VLIZ, FPS Health and Belspo propose input indicators in the OECD Scientific and 
Technological Indicators Database. This database lists a number of input 
indicators related to R&D, such as gross domestic expenditure on research and 
experimental development (GERD) and financing patterns, to measure the output 
of scientific and technological activities. In particular, it contains three proxy 
indicators for innovation that could be useful in this regard: patents, the 
technology balance of payments and trade in R&D intensive industries. Also the 
Marine Biotechnology Working Group of the Marine Board (European Science 
Foundation) attempted to map indicators of success and found that it was very 
difficult, and in some cases impossible, to obtain the necessary information. The 
working group was able to measure some key parameters of scientific outputs: 
funds and manpower devoted to marine research and technological development; 
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scientific publications and their impact (citations); European patents by marine 
science and technology sectors; and information on the objectives, current status 
and results of various research and technological development initiatives and 
programmes, both at national and European level. However, information 
pertaining to businesses and economic outputs was hard or expensive to obtain 
and difficult to interpret (OECD, 2013b).  
 
Ethics and sustainability 
In order to avoid negative environmental and social impacts VLIZ, FPS Health and 
Belspo suggest following measures to be taken at EU level: 
 create a clear legal framework, both at the global level (ex: through an 
UNCLOS Implementing Agreement, through the ratification of the Nagoya 
Protocol,…), as at EU level. A legal framework concerning environmental 
indicators which could contribute to effective resource management and 
protection protocols could be further developed.  
 apply the precautionary approach.  
 have a clear procedure for environmental impact assessments, incl. 
consequences when the impacts are thought to be negative.  
 support initiatives that categorize marine biotechnology and research, such as 
the joint Belgian, UNEP database on bioprospection in Antarctica 
(http://www.bioprospector.org/bioprospector/antarctica/home.action)  
 develop and support initiatives for the transition to a more sustainable and 
resilient society 
Suggestions for biological, geological, chemical and physical indicators that 
characterise the health of coastal waters, the nature of pollutants and their 
relation to human activities and urban concentration are being made in OECD 
(2013b). Further work is required to:  
o define and analyse the policy value of relevant quantitative indicators.  
o identify existing primary science and technology indicators and 
socioeconomic data on a sectoral and national basis. 
o analyse the validity and relevance of such indicators and data for 
policy development, such as a demonstration of sustainable 
development options adapted to regions.  
o synthesise existing indicators with a view to developing international 
indicators, including benchmarking of indicators and practice.  
o publish and disseminate regular reports on the state of the ocean and 
on marine activities based on these indicators. 
A coordinated approach to the conversation, sustainable use and sharing of the 
benefits of marine biodiversity, should be considered using the most efficient tool. 
Other useful tools related to the marine environment that should be considered 
are the Aichi Targets. 
    
22 | P a g e  
PIB_2014_001  8 May 2014  
REFERENCES  AND  BIBLIOGRAPHY 
 
COM (2012) 494 final: Communication from the Commission to the European Parliament, 
the Council, the European Economic and Social Committee and the Committee of the 
Regions - Blue Growth: Opportunities for Marine and Maritime Sustainable Growth. 
CSA MarineBiotech Public Report: Final Conference, Brussels Belgium on 11-12 March 
2013, http://www.marinebiotech.eu/ 
CSA MarineBiotech Deliverable D3.6 (2013): “Marine Biotechnology RTDI in Europe 
Strategic Analysis” http://www.marinebiotech.eu/ 
Marine Board-ESF Position Paper 15 (2010): “Marine Biotechnology: A New Vision and 
Strategy for Europe” (EMB Position Paper 15) http://www.marineboard.eu/ 
OECD, Key Biotechnology Indicators (2013a), http://oe.cd/kbi. 
OECD (2013b), Marine Biotechnology: Enabling Solutions for Ocean Productivity and 
Sustainability, OECD Publishing. 
OECD Scientific and Technological Indicators Database, 2013/2. 
UNEP, CBD, ATCM XXXVI Resolution 6 (2013): Biological Prospecting in Antarctica and its 
Belgian Preparatory Paper, United Nations University. 
